Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Machine learning-driven discovery of potent isocitrate dehydrogenase 1 mutant inhibitors from ultralarge ligand libraries for targeting malignant glioma.

The Journal of pharmacology and experimental therapeutics - 1 Apr 2026

Zaka Mehreen, Asaad Fareed, Özkanca Şeyma, Çelebi Asuman, Zhou Rui, Kim Hangun, Kılıç Türker, Avşar Timuçin, Durdağı Serdar

Abstract excerpt

Glioblastoma (GBM) represents one of the most lethal and therapy-resistant forms of brain tumors, characterized by high heterogeneity, metabolic reprogramming, and recurrence. In the current study, we aimed to identify novel small molecule inhibitors targeting mutant isocitrate dehydrogenase 1 (IDH1), a crucial enzyme involved in GBM tumor metabolism. For this aim, machine learning-based quantitative...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Discovery
Share to Glioma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Isocitrate Dehydrogenase

Share to Machine Learning

Share to Molecular Docking Simulation

Share to Molecular Dynamics Simulation

Share to Quantitative Structure-Activity Relationship

Share to Small Molecule Libraries

Source

Identifiers

PMID: 41880802
DOI: 10.1016/j.jpet.2026.103811

Genes

IDH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Machine learning-driven discovery of potent isocitrate dehydrogenase 1 mutant inhibitors from ultralarge ligand libraries for targeting malignant glioma.PMID 41880802Read ↗

Pharmacophore-based Identification of Potential Mutant Isocitrate Dehydrogenases I/2 Inhibitors: An Explorative Avenue in Cancer Drug Design.Semantic proximity Read ↗

Water Networks and Correlated Motions in Mutant Isocitrate Dehydrogenase 1 (IDH1) Are Critical for Allosteric Inhibitor Binding and Activity.Semantic proximity Read ↗

Challenges for the development of mutant isocitrate dehydrogenases 1 inhibitors to treat glioma.Semantic proximity Read ↗

Virtual mutagenesis of isocitrate dehydrogenase 1 involved in glioblastoma multiforme.Semantic proximity Read ↗

Cancer-Associated IDH1 Promotes Growth and Resistance to Targeted Therapies in the Absence of Mutation.Semantic proximity Read ↗

Identification and characterization of a novel mutant isocitrate dehydrogenase 1 inhibitor for glioma treatment.Semantic proximity Read ↗

In-silico lead identification of the pan-mutant IDH1 and IDH2 inhibitors to target glioblastoma.Semantic proximity Read ↗

Integrated analysis of mitochondrial ETC inhibition reveals genotype-specific heterogeneity of drug response in glioblastoma.Semantic proximity Read ↗

Generation, characterization, and drug sensitivities of 12 patient-derived IDH1-mutant glioma cell culturesSemantic proximity Read ↗

Exploiting the therapeutic vulnerability of IDH-mutant gliomas with zotiraciclibSemantic proximity Read ↗

Comprehensive exploration of isocitrate dehydrogenase (IDH) mutations: Tumorigenesis, drug discovery, and covalent inhibitor advances.Semantic proximity Read ↗

Generation, characterization and drug sensitivities of twelve patient-derived IDH1 mutant glioma cell culturesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.